Syndax Pharmaceuticals Files 8-K

TL;DR

Syndax Pharma filed an 8-K on 11/15, updating corporate info. All good.

AI Summary

Syndax Pharmaceuticals, Inc. filed an 8-K on November 15, 2024, reporting other events and financial statements. The filing details the company's principal executive offices located at 35 Gatehouse Drive, Building D, Floor 3, Waltham, Massachusetts, 02451, and its telephone number is (781) 419-1400. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This 8-K filing provides updated corporate information and signals ongoing regulatory compliance for Syndax Pharmaceuticals, Inc.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not contain material non-public information that would typically impact stock price.

Key Players & Entities

• Syndax Pharmaceuticals, Inc. (company) — Registrant
• November 15, 2024 (date) — Date of earliest event reported
• 35 Gatehouse Drive, Building D, Floor 3, Waltham, Massachusetts, 02451 (location) — Principal Executive Offices
• (781) 419-1400 (phone_number) — Registrant's Telephone Number
• Delaware (location) — State of Incorporation
• 1231 (date) — Fiscal Year End

FAQ

Filing Documents

• sndx-20241115.htm (8-K) — 43KB
• sndx-ex99_1.htm (EX-99.1) — 54KB
• img199102934_0.jpg (GRAPHIC) — 14KB
• 0000950170-24-127708.txt ( ) — 231KB
• sndx-20241115.xsd (EX-101.SCH) — 25KB
• sndx-20241115_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On November 15, 2024, Syndax Pharmaceuticals, Inc. (the " Company ") issued a press release announcing that the U.S. Food and Drug Administration has approved Revuforj (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (" R/R ") acute leukemia with a lysine methyltransferase 2A gene (" KMT2A ") translocation in adult and pediatric patients one year and older. A copy of the press release is filed herewith as Exhibit 99.1. The Company is holding a conference call regarding the announcement on November 15, 2024. The information contained in the press release is incorporated by reference into this Current Report on Form 8-K.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains "forward-looking statements," including, but not limited to, statements regarding the Company's plans to make Revuforj commercially available for patients with R/R acute leukemia with a KMT2a translocation. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "could," "expects," "plans," "anticipates," "believes," and similar expressions intended to identify forward-looking statements. These statements reflect the Company's current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Any forward-looking statements set forth in this Current Report speak only as of the date of this Current Report. The Company does not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated November 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNDAX PHARMACEUTICALS, INC. Date: November 15, 2024 By: /s/ Michael A. Metzger Michael A. Metzger Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR